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Introduction
Women with cervical intraepithelial lesions that confer an increased risk of cervical cancer are identified by cytological screening 1 . Policies for follow-up after finding atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) in cytology vary from repeat cytology [2] [3] [4] to immediate referral for colposcopy and biopsy [5] [6] [7] [8] . Referral of all women with ASCUS/LSIL in cytology to the colposcopy clinic and the subsequent histological examination yields substantial costs for the health care system 9 and often creates feelings of anxiety and discomfort for the women concerned 10, 11 . Given the key etiological role of oncogenic human papillomavirus (HPV) infections in the development of cervical cancer 12 , HPV testing is useful as a triage method to select women at increased risk of cervical cancer, thus justifying referral for colposcopic exploration 13, 14 . A major 3-way randomised trial comparing HPV triaging, repeat cytology and colposcopy of all women found that repeat cytology was inferior for managing ASCUS smears and that HPV triaging and colposcopy of all women were equivalent in terms of safety 15 .
The Hybrid Capture II method (HCII) is one of only 2 HPV testing methods approved by the United States Food and Drug Administration (US FDA). The HCII contains cocktails of typespecific probes, one "low-risk" (LR) mix and one "high-risk" (HR) mix containing 13 different HPV so-called "high-risk" HPV types. HCII does not provide information regarding the specific HPV type. Since different so-called "high-risk" types have substantially different risks for CIN III and cancer [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , HPV genotyping should be relevant for HPV triaging. We have compared the key test performance indices of an HPV test without typing (HCII) to test results for specific HPV types obtained using general primer PCR with GP 5+/6+ primers followed by bead-based multiplex-genotyping on the Luminex platform.
Materials and methods

Study design
In Sweden, all women aged 23-49 years are invited for cervical cancer screening at 3-yearly intervals and women aged 50-60 at 5-yearly intervals. HPV DNA genotyping PCR using the general primer pair GP5+/bioGP6+, was performed as previously described 28 .
Briefly, 1 l of extracted DNA was added to the PCR master mix in a final volume of 25 l. 
Statistical analysis
Odds ratios (OR) with 95% confidence intervals (CI) were calculated using binomial logistic regression using the software R v2.7.2 (www.r-project.com). When evaluating the usefulness of a diagnostic test result, it is important to compare the probability of disease before and after the testing. In the cohort genotyped in this paper, the pre-test probability of CIN III+ was 11.2%. For most of the HR HPV types, a positive test result resulted in a decreased (<11.2%) post-test probability of CIN III+ (equivalent to an OR of less than 1). The decreased probability was not statistically significant for any individual HR type, but there was a highly significantly decreased post-test probability for CIN III+ in case of positivity for any HR type other than HPV16/31/33 or for LR types.
Results
Altogether
For the purpose of evaluating predictive ability of a triaging test, the crude (unadjusted) OR is the relevant comparison parameter. The adjusted OR analysis rather seeks to evaluate the etiology of the risk prediction, which is not relevant for the actual triaging. E.g., the strongly decreased OR for a LR positive test is essentially eliminated by adjusting for other HPV
types. This indicates that a LR HPV infection does not in itself protect against CIN III+.
Rather, a LR HPV positive test decreases the risk for CIN III+ simply because the test is not positive for a HR type. A weak risk predictive ability by age was removed by adjustment, suggesting that the predictive ability of age was explained by an age-dependent presence of a strong risk factor, e.g. an association of HPV16 with younger cases.
The sensitivity for HCII was close to 100% for CIN II+ and CIN III+, but a few women with CIN II+ were HCII-positive but not positive for any one of the HR HPV types. The small difference in sensitivity between HCII and PCR (counting only HR HPV-positivity as positive) was due to the fact that a few cases of CIN II+ were positive for LR HPV types.
Since we did not re-review the histopathological diagnoses, it is possible that some of the cases of CIN II+ could have been downgraded to CIN I on re-review. Some of the probes used in HCII are known to cross-react with several low-risk types 31 . The fact that some samples are falsely reported as HR-positive by HCII results in a lower cost efficiency when HPV-testing with HCII is used in triaging and unnecessary anxiety for the women who are presented with a false HR positive HPV-test.
For the present scientific study, we chose to use a non-commercial assay with open access availability. The test is based on the classical GP5+/6+ PCR system that has been validated in studies encompassing several hundred thousand women and is considered a reference test in the field 32 .
Our study aimed to assess the predictive value of different HPV genotypes as such, not to evaluate a particular HPV assay. We recently performed a global proficiency study of 32 different HPV genotyping assays in terms of how well they accurately detect and genotype HPV 33 . As the assay used in the present study was found to be 100% proficient, our results are most likely generalizable to any proficient HPV genotyping assay.
HPV18 positivity did not confer any increased risk for CIN III+, which may appear surprising since HPV18 is the second most common HPV type in invasive cervical cancer 34 . HPV18
differs from HPV16 and its relatives HPV31/33 in that HPV18 is preferentially found in cervical adenocarcinoma. Cervical cytological screening is not very effective for preventing cervical adenocarcinoma and it is possible that the primary screening test (cytology) does not adequately identify the precursor lesions caused by HPV18. Furthermore, reports that have found increased CIN III+ risks for HPV18-positive women on long-term follow-up have found that these CIN III+ lesions appear more delayed after the HPV testing compared to the HPV16-associated CIN III+ lesions 17 .
For clinical interpretation of the data obtained from HPV genotyping, it will be useful to provide an accurate ascertainment of the risks that are being conferred for each one of the socalled "high-risk" HPV types. HPV genotyping data from the ASCUS/LSIL triage study (ALTS) is consistent with the data in the present report, with HPV 16 being outstanding in associating with the highest risk for CIN III 35 Indeed, it should be noted that even though the present study provided full genotyping data for >1500 women, the statistical power is still It should also be mentioned that HPV persistence is known to greatly increase the risk for CIN 
